Developer docs
API playgroundTry for free, no card

Search company profiles

Panazee

Full company profile

uuid000ansv

Namestring
Panazee
Websiteurl
panazee.me
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Panazee is a privately held, Berkeley-based health technology company founded in 2021 that has built an ultra-high resolution biomarker platform. The company positions the platform for three end markets: academic and commercial research applications, clinical point-of-care diagnostics, and consumer home testing for personal inner-health monitoring. Its core value proposition is enabling biomarker detection and measurement at high resolution in scenarios where turnaround time matters ("minutes that matter"), suggesting an underlying sensor or assay technology combined with a readout layer rather than purely a software product.

The company operates with a small team of 1–10 employees and is pre-commercial or very early commercial based on available signals: no pricing is publicly disclosed, no customer logos are named, and no management team information is available in the source material. The sole named product is its biomarker platform, with no secondary product lines, mobile app, or API offering documented. Distribution and marketing channels are not specified. Operating status is indicated as active via a live website (panazee.me).

Panazee's business model is not explicitly disclosed. It has secured two early-stage funding rounds in March and April 2022 from Calm/Storm VC and JALE Beteiligungs GmbH, respectively, though disclosed amounts are listed at zero (likely meaning undisclosed rather than literal zero). There is no evidence of revenue, ARR, subscription pricing, hardware sales, or licensing arrangements. Given the absence of pricing details and the breadth of target use cases (research, clinical, consumer), the company appears to still be defining its go-to-market motion.

Short descriptiontext

Panazee is a Berkeley-based health technology company, founded in 2021, that has developed an ultra-high resolution biomarker platform targeting academic and commercial research, point-of-care clinical diagnostics, and consumer home health monitoring applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPaxton, United States
HQ citystring
Paxton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biomarker detection platform, point-of-care diagnostics, health monitoring technology, ultra-high resolution sensing, home diagnostic testing
Industry3 codes
PRIMARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Laboratories621511
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Diagnostic Biomarker Platform
No data
Cost components2 values
Technology or R&D, Personnel
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Core offering1 text field

Panazee develops an ultra-high resolution biomarker platform designed to detect and measure biomarkers at high accuracy and precision. The platform is intended to serve three application areas: research use in academic and commercial laboratories, point-of-care diagnostic testing in clinical settings, and home-based health monitoring for individual consumers seeking to track their inner health.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Panazee offers a single unified product — its ultra-high resolution biomarker platform — which serves research applications, point-of-care diagnostics, and home testing use cases. The platform enables users to monitor their inner health.

Product and service1 record
1Biomarker Platform
CategoryDiagnostic Biomarker Platform
Description

Ultra-high resolution biomarker platform designed to detect and measure biomarkers at high accuracy and precision for research applications, point-of-care diagnostics, and home testing. It enables researchers, clinicians, and individual consumers to monitor inner health through biomarker-based analysis.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Quanterix's Simoa platform offers ultra-sensitive single-molecule biomarker detection for research and diagnostic applications. It is the most directly comparable ultra-high-resolution biomarker technology company to Panazee in both technology positioning and customer base.

TypeDirect peer
Description

Olink provides high-sensitivity biomarker analysis platforms (Proximity Extension Assay) for protein biomarker discovery and translational research. It directly competes for the same research-use biomarker platform customers Panazee targets.

TypeDirect peer
Description

Cytek provides high-resolution cell-analysis and biomarker profiling instruments for research and clinical flow cytometry. It shares Panazee's positioning around high-resolution, instrumentation-based biomarker measurements in research and translational settings.

TypeEmerging player
Description

Healthy.io turns smartphone cameras into clinical-grade home diagnostic tests (e.g., urinalysis). It overlaps with Panazee's home-testing use case from a consumer diagnostic workflow angle.

TypeDirect peer
Description

SomaLogic operates a proteomics biomarker discovery and measurement platform (SomaScan) used by academic and pharma researchers. It is a direct peer to Panazee's research-application biomarker platform business.

TypeBroad incumbent
Description

Roche Diagnostics is a global leader in clinical chemistry, immunoassays, and POC diagnostics. It defines the competitive ceiling for biomarker-based clinical diagnostic platforms Panazee would need to clear.

TypeBroad incumbent
Description

Bio-Techne sells a broad portfolio of research-use biomarker reagents, kits, and instruments (including ProteinSimple platforms). It overlaps with Panazee's research-tools positioning but spans much wider life-sciences reagent categories.

TypeDirect peer
Description

MSD offers multiplexed electrochemiluminescence biomarker detection platforms widely used in pharma, clinical, and academic research labs. Comparable in instrument-based biomarker workflow to Panazee's platform.

9Abbott Diagnostics
TypeBroad incumbent
Description

Abbott operates large-scale POC diagnostic platforms (e.g., i-STAT, ARCHITECT) and consumer/biomarker products. It is the incumbent analogue for Panazee's eventual POC and home-testing ambitions.

10Cue Health
TypeEmerging player
Description

Cue Health developed a molecular at-home diagnostic platform marketed to consumers and point-of-care settings. Comparable to Panazee's home-testing and POC use cases, with a similar small-instrument consumer positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Panazee

Diagnostic Biomarker Platformpanazee.me

Panazee is a Berkeley-based health technology company, founded in 2021, that has developed an ultra-high resolution biomarker platform targeting academic and commercial research, point-of-care clinical diagnostics, and consumer home health monitoring applications.

What Panazee does

Panazee is a privately held, Berkeley-based health technology company founded in 2021 that has built an ultra-high resolution biomarker platform. The company positions the platform for three end markets: academic and commercial research applications, clinical point-of-care diagnostics, and consumer home testing for personal inner-health monitoring. Its core value proposition is enabling biomarker detection and measurement at high resolution in scenarios where turnaround time matters ("minutes that matter"), suggesting an underlying sensor or assay technology combined with a readout layer rather than purely a software product.

The company operates with a small team of 1–10 employees and is pre-commercial or very early commercial based on available signals: no pricing is publicly disclosed, no customer logos are named, and no management team information is available in the source material. The sole named product is its biomarker platform, with no secondary product lines, mobile app, or API offering documented. Distribution and marketing channels are not specified. Operating status is indicated as active via a live website (panazee.me).

Panazee's business model is not explicitly disclosed. It has secured two early-stage funding rounds in March and April 2022 from Calm/Storm VC and JALE Beteiligungs GmbH, respectively, though disclosed amounts are listed at zero (likely meaning undisclosed rather than literal zero). There is no evidence of revenue, ARR, subscription pricing, hardware sales, or licensing arrangements. Given the absence of pricing details and the breadth of target use cases (research, clinical, consumer), the company appears to still be defining its go-to-market motion.

Panazee firmographics

Firmographics
Name
Panazee
Website
https://panazee.me
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Panazee is a Berkeley-based health technology company, founded in 2021, that has developed an ultra-high resolution biomarker platform targeting academic and commercial research, point-of-care clinical diagnostics, and consumer home health monitoring applications.
Ownership category
akta.pro rank

Panazee industry classification

Industry
Product category
Diagnostic Biomarker Platform
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Biomarker detection platform
  • Point-of-care diagnostics
  • Health monitoring technology
  • Ultra-high resolution sensing
  • Home diagnostic testing

Where Panazee is headquartered

Location

Headquarters

HQ city
Paxton
HQ country
United States
HQ region
North America

Markets served

Panazee business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Technology or R&D, Personnel

Panazee product offering

Product offering

Core offering

Panazee develops an ultra-high resolution biomarker platform designed to detect and measure biomarkers at high accuracy and precision. The platform is intended to serve three application areas: research use in academic and commercial laboratories, point-of-care diagnostic testing in clinical settings, and home-based health monitoring for individual consumers seeking to track their inner health.

Product overview

Panazee offers a single unified product — its ultra-high resolution biomarker platform — which serves research applications, point-of-care diagnostics, and home testing use cases. The platform enables users to monitor their inner health.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biomarker Platform Ultra-high resolution biomarker platform designed to detect and measure biomarkers at high accuracy and precision for research applications, point-of-care diagnostics, and home testing. It enables researchers, clinicians, and individual consumers to monitor inner health through biomarker-based analysis.

Companies that use Panazee

Customer profile

Segments3 records

Ideal customer profiles3 records

Panazee technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Panazee partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights4 records

Panazee competitors and assessment

Company assessment

Direct peers

  • Quanterix: Quanterix's Simoa platform offers ultra-sensitive single-molecule biomarker detection for research and diagnostic applications. It is the most directly comparable ultra-high-resolution biomarker technology company to Panazee in both technology positioning and customer base.
  • Olink: Olink provides high-sensitivity biomarker analysis platforms (Proximity Extension Assay) for protein biomarker discovery and translational research. It directly competes for the same research-use biomarker platform customers Panazee targets.
  • Cytek Biosciences: Cytek provides high-resolution cell-analysis and biomarker profiling instruments for research and clinical flow cytometry. It shares Panazee's positioning around high-resolution, instrumentation-based biomarker measurements in research and translational settings.
  • SomaLogic: SomaLogic operates a proteomics biomarker discovery and measurement platform (SomaScan) used by academic and pharma researchers. It is a direct peer to Panazee's research-application biomarker platform business.
  • Meso Scale Diagnostics: MSD offers multiplexed electrochemiluminescence biomarker detection platforms widely used in pharma, clinical, and academic research labs. Comparable in instrument-based biomarker workflow to Panazee's platform.

Emerging players

  • Healthy.io: Healthy.io turns smartphone cameras into clinical-grade home diagnostic tests (e.g., urinalysis). It overlaps with Panazee's home-testing use case from a consumer diagnostic workflow angle.
  • Cue Health: Cue Health developed a molecular at-home diagnostic platform marketed to consumers and point-of-care settings. Comparable to Panazee's home-testing and POC use cases, with a similar small-instrument consumer positioning.

Broad incumbents

  • Roche Diagnostics: Roche Diagnostics is a global leader in clinical chemistry, immunoassays, and POC diagnostics. It defines the competitive ceiling for biomarker-based clinical diagnostic platforms Panazee would need to clear.
  • Bio-Techne: Bio-Techne sells a broad portfolio of research-use biomarker reagents, kits, and instruments (including ProteinSimple platforms). It overlaps with Panazee's research-tools positioning but spans much wider life-sciences reagent categories.
  • Abbott Diagnostics: Abbott operates large-scale POC diagnostic platforms (e.g., i-STAT, ARCHITECT) and consumer/biomarker products. It is the incumbent analogue for Panazee's eventual POC and home-testing ambitions.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

Panazee financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Panazee leadership team

Management profile

Number of profiles

Panazee funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Panazee M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panazee

What does Panazee do?

Panazee develops an ultra-high resolution biomarker platform designed to detect and measure biomarkers at high accuracy and precision. The platform is intended to serve three application areas: research use in academic and commercial laboratories, point-of-care diagnostic testing in clinical settings, and home-based health monitoring for individual consumers seeking to track their inner health.

Is Panazee a public or private company?

Panazee is a private company. It is classified as venture growth investor backed and is currently operating.

When was Panazee founded?

Panazee was founded in 2019. It employs 1 to 10 people.

Where is Panazee based?

Panazee is headquartered in Paxton, United States, in the North America region.

Who are Panazee's main competitors?

Direct peers on record are Quanterix, Olink, Cytek Biosciences, SomaLogic and Meso Scale Diagnostics. Emerging players are Healthy.io and Cue Health. Broad incumbents are Roche Diagnostics, Bio-Techne and Abbott Diagnostics.

Does Panazee have an API?

No public API is recorded for Panazee.

What industry is Panazee in?

Panazee's product category is Diagnostic Biomarker Platform. Its primary akta.pro industry code is HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 334516 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales